Continuous Subcutaneous Insulin Infusion Alters MicroRNA Expression and Glycaemic Variability in Children with Type 1 Diabetes

Emma S Scott; Andrzej S Januszewski; Luke M Carroll; Gregory R Fulcher; Mugdha V Joglekar; Anandwardha A Hardikar; Timothy Jones; Elizabeth Davis; Alicia J. Jenkins

doi:10.1038/s41598-021-95824-8

Continuous Subcutaneous Insulin Infusion Alters MicroRNA Expression and Glycaemic Variability in Children with Type 1 Diabetes

Emma S Scott, Andrzej S Januszewski, Luke M Carroll, Gregory R Fulcher, Mugdha V Joglekar, Anandwardha A Hardikar, Timothy Jones, Elizabeth Davis, Alicia J. Jenkins

Paediatrics

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

To determine whether continuous subcutaneous insulin infusion (CSII) vs. multiple daily injections (MDI) therapy from near-diagnosis of type 1 diabetes is associated with reduced glycaemic variability (GV) and altered microRNA (miRNAs) expression. Adolescents (74% male) within 3-months of diabetes diagnosis (n = 27) were randomized to CSII (n = 12) or MDI. HbA1c, 1-5-Anhydroglucitol (1,5-AG), high sensitivity C-peptide and a custom TaqMan qPCR panel of 52 miRNAs were measured at baseline and follow-up (median (LQ-UQ); 535 (519–563) days). There were no significant differences between groups in baseline or follow-up HbA1c or C-peptide, nor baseline miRNAs. Mean ± SD 1,5-AG improved with CSII vs. MDI (3.1 ± 4.1 vs. − 2.2 ± − 7.0 mg/ml respectively, P = 0.029). On follow-up 11 miRNAs associated with diabetes vascular complications had altered expression in CSII-users. Early CSII vs. MDI use is associated with lower GV and less adverse vascular-related miRNAs. Relationships with future complications are of interest.

Original language	English
Article number	16656
Journal	Scientific Reports
Volume	11
Issue number	1
Early online date	17 Aug 2021
DOIs	https://doi.org/10.1038/s41598-021-95824-8
Publication status	Published - Dec 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41598-021-95824-8Licence: CC BY

Jones Improving the Lives of Young People with Type 1 Diabetes using State of the Art Therapies
Jones, T. (Investigator 01), Davis, E. (Investigator 02), Fournier, P. (Investigator 03), Keenan, D. (Investigator 04), Grey, M. (Investigator 05), Weinzimer, S. (Investigator 06), Geelhoed, E. (Investigator 07), Cross, D. (Investigator 08) & Tamborlane, W. (Investigator 09)
NHMRC National Health and Medical Research Council
1/01/15 → 30/04/21
Project: Research

Cite this

@article{58f291c2899b4c7c85332648e2e68d58,

title = "Continuous Subcutaneous Insulin Infusion Alters MicroRNA Expression and Glycaemic Variability in Children with Type 1 Diabetes",

abstract = "To determine whether continuous subcutaneous insulin infusion (CSII) vs. multiple daily injections (MDI) therapy from near-diagnosis of type 1 diabetes is associated with reduced glycaemic variability (GV) and altered microRNA (miRNAs) expression. Adolescents (74% male) within 3-months of diabetes diagnosis (n = 27) were randomized to CSII (n = 12) or MDI. HbA1c, 1-5-Anhydroglucitol (1,5-AG), high sensitivity C-peptide and a custom TaqMan qPCR panel of 52 miRNAs were measured at baseline and follow-up (median (LQ-UQ); 535 (519–563) days). There were no significant differences between groups in baseline or follow-up HbA1c or C-peptide, nor baseline miRNAs. Mean ± SD 1,5-AG improved with CSII vs. MDI (3.1 ± 4.1 vs. − 2.2 ± − 7.0 mg/ml respectively, P = 0.029). On follow-up 11 miRNAs associated with diabetes vascular complications had altered expression in CSII-users. Early CSII vs. MDI use is associated with lower GV and less adverse vascular-related miRNAs. Relationships with future complications are of interest.",

author = "Scott, {Emma S} and Januszewski, {Andrzej S} and Carroll, {Luke M} and Fulcher, {Gregory R} and Joglekar, {Mugdha V} and Hardikar, {Anandwardha A} and Timothy Jones and Elizabeth Davis and Jenkins, {Alicia J.}",

year = "2021",

month = dec,

doi = "10.1038/s41598-021-95824-8",

language = "English",

volume = "11",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "Nature Publishing Group - Macmillan Publishers",

number = "1",

}

TY - JOUR

T1 - Continuous Subcutaneous Insulin Infusion Alters MicroRNA Expression and Glycaemic Variability in Children with Type 1 Diabetes

AU - Scott, Emma S

AU - Januszewski, Andrzej S

AU - Carroll, Luke M

AU - Fulcher, Gregory R

AU - Joglekar, Mugdha V

AU - Hardikar, Anandwardha A

AU - Jones, Timothy

AU - Davis, Elizabeth

AU - Jenkins, Alicia J.

PY - 2021/12

Y1 - 2021/12

N2 - To determine whether continuous subcutaneous insulin infusion (CSII) vs. multiple daily injections (MDI) therapy from near-diagnosis of type 1 diabetes is associated with reduced glycaemic variability (GV) and altered microRNA (miRNAs) expression. Adolescents (74% male) within 3-months of diabetes diagnosis (n = 27) were randomized to CSII (n = 12) or MDI. HbA1c, 1-5-Anhydroglucitol (1,5-AG), high sensitivity C-peptide and a custom TaqMan qPCR panel of 52 miRNAs were measured at baseline and follow-up (median (LQ-UQ); 535 (519–563) days). There were no significant differences between groups in baseline or follow-up HbA1c or C-peptide, nor baseline miRNAs. Mean ± SD 1,5-AG improved with CSII vs. MDI (3.1 ± 4.1 vs. − 2.2 ± − 7.0 mg/ml respectively, P = 0.029). On follow-up 11 miRNAs associated with diabetes vascular complications had altered expression in CSII-users. Early CSII vs. MDI use is associated with lower GV and less adverse vascular-related miRNAs. Relationships with future complications are of interest.

AB - To determine whether continuous subcutaneous insulin infusion (CSII) vs. multiple daily injections (MDI) therapy from near-diagnosis of type 1 diabetes is associated with reduced glycaemic variability (GV) and altered microRNA (miRNAs) expression. Adolescents (74% male) within 3-months of diabetes diagnosis (n = 27) were randomized to CSII (n = 12) or MDI. HbA1c, 1-5-Anhydroglucitol (1,5-AG), high sensitivity C-peptide and a custom TaqMan qPCR panel of 52 miRNAs were measured at baseline and follow-up (median (LQ-UQ); 535 (519–563) days). There were no significant differences between groups in baseline or follow-up HbA1c or C-peptide, nor baseline miRNAs. Mean ± SD 1,5-AG improved with CSII vs. MDI (3.1 ± 4.1 vs. − 2.2 ± − 7.0 mg/ml respectively, P = 0.029). On follow-up 11 miRNAs associated with diabetes vascular complications had altered expression in CSII-users. Early CSII vs. MDI use is associated with lower GV and less adverse vascular-related miRNAs. Relationships with future complications are of interest.

U2 - 10.1038/s41598-021-95824-8

DO - 10.1038/s41598-021-95824-8

M3 - Article

C2 - 34404828

SN - 2045-2322

VL - 11

JO - Scientific Reports

JF - Scientific Reports

IS - 1

M1 - 16656

ER -

Continuous Subcutaneous Insulin Infusion Alters MicroRNA Expression and Glycaemic Variability in Children with Type 1 Diabetes

Abstract

UN SDGs

Access to Document

Fingerprint

Projects

Jones Improving the Lives of Young People with Type 1 Diabetes using State of the Art Therapies

Cite this